Multiple sclerosis is said to be a disease in which the fatty myelin sheaths around the axons of the brain and spinal cord are impaired, thus resulting in demyelination and scarring in addition to a wide range of signs and symptoms. Scientists from Queen Mary, University of London claim that a new drug for multiple sclerosis seems to exhibit potential in treating the condition suffered by several people in UK.
A chief examination of the oral drug Cladribine has apparently exhibited that it could considerably decrease relapse and worsening of the disease. It may also get rid of the repulsive side effects connected to present therapies. Cladribine is alleged to be the first ever treatment in tablet form for MS, and only requires to be consumed for between 8 to 10 days a year, thereby removing the necessity for usual injections and intravenous infusions otherwise tolerated by sufferers. The effortlessness with which Cladribine tablets may be administered, pooled with its comparatively few side effects, could make it an immensely exhilarating progress in the arena of MS.
Multiple sclerosis is claimed to be an immobilizing neurological condition which typically begins in young adulthood. It supposedly results from the body’s own immune system impairing the central nervous system. This may hamper with the spread of messages between the brain and other portion of the body and may lead to issues with vision, muscle control, hearing and memory. Cladribine tablets supposedly function by repressing the immune system thus curtailing its capability to further assault the central nervous system.
The study was headed by Professor Gavin Giovanonni from Barts and the London School of Medicine and Dentistry. The study included more than 1,300 MS patients who were trailed for almost two years and examined via MRI scans. Patients apparently received either two or four small treatment courses of Cladribine tablets for each year, or a placebo. Every course may comprise of one or two tablets each day for 4 or 5 days, thereby adding up to simply 8 to 20 days of treatment every year.
Professor Giovanonni commented, “The introduction of an oral therapy that is simple and easy to use is a big step forward for people with MS who have been patiently waiting for an oral therapy for decades. The benefits of oral Cladribine as a first line therapy will need to be weighed against the potential long term risks.”
As opposed to patients who were receiving the placebo, those consuming Cladribine tablets appeared to be more than 55 per cent less liable to experience relapse, and around 30 per cent less expected to undergo deterioration in their disability owing to MS.
The study was published online in the New England Journal of Medicine.